Politics and Policy of Controlled Substances in View of the Opioid Overdose Crisis

January 30, 2018 9:15am

James Arnold
Liaison and Policy Section Chief
Drug Enforcement Administration (Springfield, VA)

Michael Klein, Ph.D.
Senior Director Regulatory Affairs Coté Orphan, a Quintiles Company (Silver Spring, MD)
Former Director Controlled Substance Staff Food and Drug Administration’s Center for Drug Evaluation and Research

Louis Milione
Senior Managing Director Guidepost Solutions LLC (New York, NY)
Former Assistant Administrator Office of Diversion Control Drug Enforcement Administration

Shruti Kulkarni
Center for Lawful Access and Abuse Deterrence Associate

Associate (licensed to practice in Maryland. DC application pending)
DCBA Law & Policy (Washington, DC)


John A. Gilbert Jr.
Hyman, Phelps & McNamara, PC (Washington, DC)

Our nation is in trouble. Preliminary New York Times data shows that between 59,000-65,000 people died from drug overdoses in 2016, and the death toll continues to rise in 2017. This roundtable session will bring together key policy leaders from industry organizations to provide their input as to how our nation got here, current initiatives, recent and pending legislation, DEA notices and FDA Guidances, REMs updates, patient access, and other happenings on the Hill. Our panelists will discuss their best options for the future and for ending the opioid overdose epidemic.